Drug Discovery
By
Could Merck’s Oral PCSK9 Inhibitor Enlicitide Transform Cholesterol Management?
Key Takeaways Breakthrough in Cardiovascular Innovation Merck announced positive topline Phase 3 results for enlicitide decanoate, its investigational…
Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Key Highlights: Collaboration to Accelerate Clinical DevelopmentVeeva Systems announced a landmark collaboration with Amgen to transform clinical trial…
Can Johnson & Johnson’s $5B+ Immunology Bet Survive After Nipocalimab’s Rheumatoid Arthritis Setback?
Key Highlights: A Trial Disappointment, Not the EndgameJohnson & Johnson announced the discontinuation of nipocalimab development in rheumatoid…
Could Roche and Alnylam’s Phase III Trial of Zilebesiran Redefine Hypertension Care for 1.2 Billion Patients Worldwide?
Key Highlights Phase II Data Paves the WayThe KARDIA clinical program—spanning three Phase II trials—has provided the foundation…
Pfizer Provides 2026 Financial Guidance and Updates 2025 Revenue Outlook
New York, NY – Pfizer Inc. (NYSE: PFE) today announced its financial guidance for the full year 2026…
Pfizer Celebrates Innovation with 2025 AI Festival
Global – Pfizer hosted its second annual AI Festival Week, bringing together colleagues worldwide to explore the transformative…
